Discovered in 1982, the bacterium Helicobacter pylori was regarded as a group I carcinogen by the International Agency for Research on Cancer (IARC) in 1994. Current consensus considers the microorganism a serious latent infectious disease, treated similar to tuberculosis and syphilis. The bacterium is considered a crucial pathogen responsible for >80-90% of gastric adenocarcinoma. Evidence from cohort studies suggests that curing an H. pylori infection can prevent gastric cancer. Indeed, due to effective diagnosis and H. pylori treatment, gastric cancer went from ranking first in most common cancers in 1975, to the fifth most common today. However, the rapid increase in antibiotic resistance has significantly decreased the effectiveness of treatment. Unable to achieve expected results, conventional therapies are no longer as useful. As such a challenge has emerged, of interest to all clinicians.
New/alternative therapeutic agents or therapies are needed to increase chances for a higher cure rate. To explore these issues, this Research Topic will include both original papers and reviews related to: (1) new guidelines, treatment therapies, vaccines or major drugs for the management of an H. pylori infection; (2) use of natural resources such as herbal medicines and probiotics as supplements for more effective H. pylori treatment; (3) mechanisms of novel mutations in antibiotic resistance to provide the novel therapeutic targets and treatment options, (4) evidence from clinical trials to validate the effect of these new findings.
Since the resistance patterns and extents vary from country to country and region to region, we also welcome systematic and meta-analysis reviews about the global burden caused by H. pylori; the effects of different therapies; and global antibiotic resistance related to genotype patterns of mutations to unravel the overview of H. pylori-related consequences.
Discovered in 1982, the bacterium Helicobacter pylori was regarded as a group I carcinogen by the International Agency for Research on Cancer (IARC) in 1994. Current consensus considers the microorganism a serious latent infectious disease, treated similar to tuberculosis and syphilis. The bacterium is considered a crucial pathogen responsible for >80-90% of gastric adenocarcinoma. Evidence from cohort studies suggests that curing an H. pylori infection can prevent gastric cancer. Indeed, due to effective diagnosis and H. pylori treatment, gastric cancer went from ranking first in most common cancers in 1975, to the fifth most common today. However, the rapid increase in antibiotic resistance has significantly decreased the effectiveness of treatment. Unable to achieve expected results, conventional therapies are no longer as useful. As such a challenge has emerged, of interest to all clinicians.
New/alternative therapeutic agents or therapies are needed to increase chances for a higher cure rate. To explore these issues, this Research Topic will include both original papers and reviews related to: (1) new guidelines, treatment therapies, vaccines or major drugs for the management of an H. pylori infection; (2) use of natural resources such as herbal medicines and probiotics as supplements for more effective H. pylori treatment; (3) mechanisms of novel mutations in antibiotic resistance to provide the novel therapeutic targets and treatment options, (4) evidence from clinical trials to validate the effect of these new findings.
Since the resistance patterns and extents vary from country to country and region to region, we also welcome systematic and meta-analysis reviews about the global burden caused by H. pylori; the effects of different therapies; and global antibiotic resistance related to genotype patterns of mutations to unravel the overview of H. pylori-related consequences.
